Clinical Trial Update: Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Ecopipam for Tourette's Syndrome in subjects aged 7-17 has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• Ecopipam (Ecopipam)

Snippet

Sponsor: Emalex Biosciences Inc. | Conditions: Tourette's Syndrome | Phase 2 | Status: COMPLETED